Three years ago, mRNA technology was a suitable but costly vaccine alternative that could not be efficiently scaled to mass. Today, it’s the basis of 589 million (and counting) doses of two life-saving COVID-19 vaccines. Almost overnight, what was previously considered a next-gen platform became a “right now” technology. Typically, vaccines take years to decades to proceed from development to approval. However, COVID-19 shrank that timeline to only months. But, quality control and testing—which normally comprises more than half of vaccine production time—could not be compromised. Luckily, modern analytical techniques were up to the challenge. Download this visual article to learn about the future of mRNA vaccines - being used for things like the HIV virus, cancer, and the nipah virus.